Safety evaluation of zotepine for the treatment of schizophrenia

Bibliography

• Falkai P, Wobrock T, Lieberman J, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6(3):132-91
   PubMed Web of Science ®Google Scholar
• Moller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000;1(4):204-14
   PubMedGoogle Scholar
• Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999;368(2-3):277-83
   PubMed Web of Science ®Google Scholar
• Green B. Zotepine: a clinical review. Expert Opin Drug Metab Toxicol 2009;5(2):181-6
   PubMed Web of Science ®Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain–a systematic review. Acta Psychiatr Scand 2000; 101(6):416-32
   PubMed Web of Science ®Google Scholar
• Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38(5):393-414
   PubMed Web of Science ®Google Scholar
• Needham PL, Atkinson J, Skill MJ, Heal DJ. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull 1996;32(1):123-8
   PubMed Web of Science ®Google Scholar
• Roth BL, Craigo SC, Choudhary MS, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268(3):1403-10
   PubMed Web of Science ®Google Scholar
• Rowley HL, Kilpatrick IC, Needham PL, Heal DJ. Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropharmacology 1998;37(7):937-44
   PubMed Web of Science ®Google Scholar
• Shiraga T, Kaneko H, Iwasaki K, Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 1999;29(3):217-29
   PubMed Web of Science ®Google Scholar
• Drug Evaluation Monograph in Drugdex Micromedex, Inc. Zotepine 1999;100. Denver, Colorado
   Google Scholar
• Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 1997;53(6):915-29
   PubMed Web of Science ®Google Scholar
• Tanaka O. Pharmacokinetics of zotepine and various factors affecting that of zotepine. Nihon Shinkei Seishin Yakurigaku Zasshi 1996;16(2):49-52
   PubMedGoogle Scholar
• Cooper SJ, Butler A, Tweed J, Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000;150(3):237-43
   PubMed Web of Science ®Google Scholar
• Moller HJ, Riedel M, Muller N, Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 2004;37(6):270-8
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Sudo T, Hirano M, Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia. Schizophr Res 2006;87(1-3):332-3
   PubMed Web of Science ®Google Scholar
• Palmgren K, Wighton A, Reynolds CW, The safety and efficacy of zotepine in the treatment of schizophrenia: Results of a one-year naturalistic clinical trial. Int J Clin Psychiatry 2000;4:299-306
   Google Scholar
• Wang PW, Wang SY, Huang CJ. Zotepine-induced spontaneous ejaculation. Int J Clin Pharmacol Ther 2008;46(11):571-3
   PubMed Web of Science ®Google Scholar
• Chen KC, Yang YK, Chen PS, Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. Psychiatry Clin Neurosci 2003;57(4):369-71
   PubMed Web of Science ®Google Scholar
• Wetterling T. Hyperlipidemia–side-effect of the treatment with an atypical antipsychotic (zotepine)? Psychiatr Prax 2002;29(8):438-40
   PubMed Web of Science ®Google Scholar
• Kubota T, Ishikura T, Jibiki I. Three cases of alopecia areata induced by zotepine. Acta Neurol (Napoli) 1993;15(3):200-3
   PubMedGoogle Scholar
• Kamble P, Chen H, Sherer JT, Aparasu RR. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging 2009;26(6):483-92
   PubMed Web of Science ®Google Scholar
• Rainer MK, Mucke HA, Kruger-Rainer C, Zotepine for behavioural and psychological symptoms in dementia: an open-label study. CNS Drugs 2004;18(1):49-55
   PubMed Web of Science ®Google Scholar
• Amann B, Sterr A, Mergl R, Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disord 2005;7(5):471-6
   PubMed Web of Science ®Google Scholar
• Harada T, Otsuki S. Antimanic effect of zotepine. Clin Ther 1986; 8(4):406-14
   PubMed Web of Science ®Google Scholar
• Lin YC, Su HK, Ouyang WC, Lane HY. Zotepine-induced QTc prolongation. J Clin Psychopharmacol 2008;28(5):576-8
   PubMed Web of Science ®Google Scholar
• Barnas C, Stuppack CH, Miller C, Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs haloperidol. Int Clin Psychopharmacol 1992;7(1):23-7
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Barnas C, Stuppack CH, Zotepine vs haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 1989;25(1):97-100
   PubMed Web of Science ®Google Scholar
• Petit M, Raniwalla J, Tweed J, A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996;32(1):81-7
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Lin SK, Lin HN. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formos Med Assoc 2001;100(12):811-6
   PubMed Web of Science ®Google Scholar
• Sarai K, Okada M. Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study. Pharmacopsychiatry 1987;20(1 Spec No):38-46
   PubMedGoogle Scholar
• Cooper SJ, Tweed J, Raniwalla J, A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 2000;101(3):218-25
   PubMed Web of Science ®Google Scholar
• Lin CC, Chen JY, Bai YM, Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2 years follow-up. J Eur Coll Neuopsychopharmacol 2006;16(Suppl 4):410
   Google Scholar
• Briken P, Nika E, Moritz S, Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophr Res 2002;57(2-3):311-13
   PubMed Web of Science ®Google Scholar
• Švestka J, Synek O, Tomanova J, Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007;28(6):881-88
   PubMed Web of Science ®Google Scholar
• Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol 2000;15(7):499-512
   PubMed Web of Science ®Google Scholar
• Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64(7):701-23
   PubMed Web of Science ®Google Scholar
• Vohora D. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Curr Opin Investig Drugs 2007;8(7):531-38
   PubMed Web of Science ®Google Scholar
• DeSilva P, Fenton M, Rathbone J. Zotepine for schizophrenia. Cochrane Database Syst Rev 2006;(4):CD001948
   Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;(1):CD006628
   Google Scholar
• Lin CC, Bai YM, Chen JY, Switching from clozapine to zotepine in schizophrenic patients: A randomized, single-blind controlled study. J Eur Coll Neuopsychopharmacol 2003;13(4):318
   Google Scholar
• Meyer-Lindenberg A, Gruppe H, Bauer U, Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30(2):35-42
   PubMed Web of Science ®Google Scholar